Viral Shedding and Susceptibility to Oseltamivir in Hospitalized Immunocompromised Patients with Influenza in the Influenza Resistance Information Study (IRIS)
Free accessResearch articleFirst published online August, 2015
Viral Shedding and Susceptibility to Oseltamivir in Hospitalized Immunocompromised Patients with Influenza in the Influenza Resistance Information Study (IRIS)
Immunocompromised patients are at greater risk of complicated influenza and may be more likely to develop antiviral resistance. This observational sub-study of the Influenza Resistance Information Study (NCT00884117) aimed to study antiviral resistance in immunocompromised patients with influenza and characterize its effect on clinical and virological outcomes.
Methods
Eligible immunocompromised patients were aged ≥1 year with a local rapid diagnostic or PCR test positive for influenza ≤96 h after diagnosis and with influenza symptoms. Nasal and throat swabs were taken for RT-PCR analysis on day 1 and then every 3 days until patients were virus-free. Resistance was assessed by mutation-specific RT-PCR, phenotypic susceptibility analysis and Sanger sequencing.
Results
Of 42 patients enrolled, 29 (69%) were influenza-positive (RT-PCR) on day 1: 18 adults and 11 children aged 1–12 years. Six patients were severely immunocompromised. On days 3, 6 and 9, most patients tested (18/24, 9/15 and 6/9, respectively) had not cleared the virus. Two of five patients assessed after day 9 continued shedding virus until day 15. H1N1pdm09 viruses harbouring H275Y mutations were detected in post-baseline samples from four patients (aged 52–61 years), one of whom had prolonged viral shedding. No genotypic antiviral resistance was detected in the other 20 treated patients (prevalence of resistance, 17%). Correlation between level of immune compromise and resistance or outcomes could not be assessed. Ten patients (seven influenza-positive) were admitted to intensive care and three died.
Conclusions
In these patients with mild/moderate immunocompromise, emergence of oseltamivir-resistant viruses was not common. Severity of influenza symptoms ranged from mild to moderate, but correlation with level of compromise could not be determined.
References
1.
BeckC.R., McKenzieB.C., HashimA.B., HarrisR.C. University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology.J Infect Dis2012; 206: 1250–1259.
2.
FioreA.E., FryA., ShayD.Antiviral agents for the treatment and chemoprophylaxis of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep2011; 60: 1–24.
PirallaA., Gozalo-MargüelloM., FiorinaL.Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011–2012 influenza season in Italy.J Clin Virol2013; 58: 132–137.
5.
MemoliM.J., AthotaR., ReedS.The natural history of influenza infection in the severely immunocompromised versus non-immunocompromised hosts.Clin Infect Dis2014; 58: 214–224.
6.
IsonM.G.Influenza, including the novel H1N1, in organ transplant patients.Curr Opin Infect Dis2010; 23: 365–373.
7.
IsonM.G., HirschH.H.Influenza: a recurrent challenge to transplantation.Transpl Infect Dis2010; 12: 95–97.
8.
KhannaN., SteffenI., StudtJ-DOutcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation.Transpl Infect Dis2009; 11: 100–105.
9.
KumarD., MichaelsM.G., MorrisM.I.Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study.Lancet Infect Dis2010; 10: 521–526.
10.
IiokaF., SadaR., MaesakoY., NakamuraF., OhnoH.Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation.Int J Hematol2012; 96: 364–369.
11.
TramontanaA.R., GeorgeB., HurtA.C.Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.Emerg Infect Dis2010; 16: 1068–1075.
12.
van der VriesE., StittelaarK.J., van AmerongenG.Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets.PLoS Pathog2013; 9: e1003343.
13.
WhitleyR.J., BoucherC.A., LinaB.Global assessment of resistance to neuraminidase inhibitors, 2008–2011: the Influenza Resistance Information Study (IRIS).Clin Infect Dis2013; 56: 1197–1205.
14.
van der VriesE., JongesM., HerfstS.Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase.J Clin Virol2010; 47: 34–37.
15.
FalconeV., BierbaumS., KernW.Influenza virus A(H1N1)pdm09 hemagglutinin polymorphism and associated disease in southern Germany during the 2010/11 influenza season.Arch Virol2013; 158: 1297–1303.
16.
ChemalyR.F., GhoshS., BodeyG.P.Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center.Medicine (Baltimore)2006; 85: 278–287.
